Trial Profile

A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF-06886992 (Primary) ; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A C Y W-135 conjugate; Paracetamol; PF 5212366
Indications Meningococcal infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Pfizer

Most Recent Events

18 Jan 2023 Status changed from active, no longer recruiting to discontinued.
06 Oct 2022 This trial has been discontinued in Germany (End Date: 15 Sep 2022) according to European Clinical Trials Database record.
05 Oct 2022 This trial has been discontinued in Greece (End Date: 15 Sep 2022) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com